Additional Information

Description

Tranexamic acid injection, available in single-dose vials, presents a pharmaceutical solution containing a concentration of 100 mg/mL of the active ingredient. This medication is primarily indicated for its antifibrinolytic properties, which serve to inhibit the breakdown of blood clots.

Tranexamic acid functions by competitively blocking lysine-binding sites on plasminogen molecules, thus preventing the conversion of plasminogen to plasmin, an enzyme responsible for fibrinolysis. This mechanism makes it efficacious in managing various conditions characterized by excessive bleeding, such as menorrhagia, postpartum hemorrhage, and surgical procedures where reduced blood loss is crucial.

Each vial of Tranexamic acid injection, with its single-dose configuration, ensures precise administration and minimizes the risk of contamination or misuse. The standardized concentration of 100 mg/mL facilitates accurate dosing, allowing healthcare professionals to tailor treatment regimens according to individual patient needs. The 10 x 10 mL packaging format offers convenience and flexibility in clinical settings, ensuring an adequate supply for various treatment durations and patient populations.

As an integral component of hemostatic therapy, Tranexamic acid injection provides a valuable adjunct to surgical procedures, particularly in specialties such as orthopedics, cardiovascular surgery, and trauma care. By effectively reducing blood loss and transfusion requirements, it contributes to improved patient outcomes and shorter recovery times.